in this issue
Regions :: Western Europe
DSM Buys Stake in Antibody Firm
10:53 AM MDT | March 18, 2008 | Chemical Week Editorial Staff
DSM Venturing, the venture capital arm of DSM, says it has made an equity investment in biotech firm IQ Therapeutics (Groningen, the Netherlands), a developer of antibodies for vaccines. DSM says it holds a“significant minority share in the business,” although financial terms were not disclosed. IQ Therapeutics’ portfolio includes an anti-anthrax vaccine, a product with “great potential,” says Karen King, president, DSM...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee